• Vfend 200 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  VORICONAZOLE	200 mg

  ATC: J02A J02AC J02AC03

• Vfend 200 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  VORICONAZOLE	200 mg

  ATC: J02A J02AC J02AC03

• Vfend 200 mg powder for solution for infusion

  Form: powder for solution for infusion

  Active substance	Dosage
  VORICONAZOLE	200 mg

  ATC: J02A J02AC J02AC03

• Vfend 40 mg/ml powder for oral suspension

  Form: powder for preparation of oral suspension

  Active substance	Dosage
  VORICONAZOLE	40 mg

  ATC: J02A J02AC J02AC03

• Vfend 50 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  VORICONAZOLE	50 mg

  ATC: J02A J02AC J02AC03

• Vizimpro 15 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  DACOMITINIB MONOHYDRATE	15.576 mg

  ATC: L01E L01EB L01EB07

• Vizimpro 30 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  DACOMITINIB MONOHYDRATE	31.153 mg

  ATC: L01E L01EB L01EB07

• Vizimpro 45 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  DACOMITINIB MONOHYDRATE	46.729 mg

  ATC: L01E L01EB L01EB07

• Vyndaqel 61 mg soft capsules

  Form: capsules, soft gelatin

  Active substance	Dosage
  TAFLAMIDIS	61 mg

  ATC: N07X N07XX N07XX08

• Xalkori 150 mg granules in capsules to open

  Form: capsules, granules for opening

  Active substance	Dosage
  CRIZOTINIB	150 mg

  ATC: L01E L01ED L01ED01

• Xalkori 20 mg granules in capsules for opening

  Form: capsules, granules for opening

  Active substance	Dosage
  CRIZOTINIB	20 mg

  ATC: L01E L01ED L01ED01

• Xalkori 200 mg hard capsules

  Form: capsules, hard

  Active substance	Dosage
  CRIZOTINIB	200,00 mg

  ATC: L01E L01ED L01ED01

• Xalkori 250 mg hard capsules

  Form: capsules, hard

  Active substance	Dosage
  CRIZOTINIB	250,00 mg

  ATC: L01E L01ED L01ED01

• Xalkori 50 mg granules in capsules for opening

  Form: capsules, granules for opening

  Active substance	Dosage
  CRIZOTINIB	50 mg

  ATC: L01E L01ED L01ED01

• Xeljanz 1 mg/ml oral solution

  Form: solution, oral

  Active substance	Dosage
  TOFACITINIB CITRATE	1,62 mg

  ATC: L04A L04AF L04AF01

• Xeljanz 10 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  TOFACITINIB CITRATE	16,155 mg

  ATC: L04A L04AF L04AF01

• Xeljanz 11 mg prolonged-release tablets

  Form: tablets, prolonged-release

  Active substance	Dosage
  TOFACITINIB CITRATE	17,77 mg

  ATC: L04A L04AF L04AF01

• Xeljanz 5 mg film-coated tablets

  Form: tablets, film-coated

  Active substance	Dosage
  TOFACITINIB CITRATE	8,078 mg

  ATC: L04A L04AF L04AF01

• Zirabev 25 mg/ml concentrate for solution for infusion

  Form: solution for infusion, concentrate

  Active substance	Dosage
  BEVACIZUMAB	400 mg

  ATC: L01F L01FG L01FG01

• Zirabev 25 mg/ml concentrate for solution for infusion

  Form: solution for infusion, concentrate

  Active substance	Dosage
  BEVACIZUMAB	100 mg

  ATC: L01F L01FG L01FG01